HIMS icon

Hims & Hers Health

49.28 USD
-17.13
25.79%
At close Feb 21, 4:00 PM EST
After hours
49.00
-0.28
0.57%
1 day
-25.79%
5 days
-17.89%
1 month
65.31%
3 months
104.06%
6 months
197.40%
Year to date
95.56%
1 year
423.70%
5 years
219.38%
10 years
219.38%
 

About: Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.

Employees: 1,046

0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

226% more first-time investments, than exits

New positions opened: 124 | Existing positions closed: 38

55% more capital invested

Capital invested by funds: $2.56B [Q3] → $3.96B (+$1.4B) [Q4]

24% more funds holding

Funds holding: 304 [Q3] → 378 (+74) [Q4]

23% more repeat investments, than reductions

Existing positions increased: 128 | Existing positions reduced: 104

11.17% more ownership

Funds ownership: 66.8% [Q3] → 77.98% (+11.17%) [Q4]

0% more call options, than puts

Call options by funds: $384M | Put options by funds: $383M

25% less funds holding in top 10

Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$21
57%
downside
Avg. target
$38
23%
downside
High target
$68
38%
upside

7 analyst ratings

positive
43%
neutral
29%
negative
29%
B of A Securities
Allen Lutz
86% 1-year accuracy
12 / 14 met price target
57%downside
$21
Underperform
Maintained
20 Feb 2025
Canaccord Genuity
Maria Ripps
79% 1-year accuracy
26 / 33 met price target
38%upside
$68
Buy
Maintained
19 Feb 2025
Morgan Stanley
Craig Hettenbach
33% 1-year accuracy
2 / 6 met price target
22%upside
$60
Equal-Weight
Downgraded
18 Feb 2025
Citigroup
Daniel Grosslight
41% 1-year accuracy
9 / 22 met price target
49%downside
$25
Sell
Downgraded
10 Jan 2025
BTIG
David Larsen
71% 1-year accuracy
12 / 17 met price target
29%downside
$35
Buy
Initiated
7 Jan 2025

Financial journalist opinion

Based on 54 articles about HIMS published over the past 30 days

Neutral
Schwab Network
16 hours ago
Overlooked Stock: HIMS
Hims & Hers Health (HIMS) sold off most of its massive rally today that it got over the last couple weeks. George Tsilis points out that the FDA no longer sees shortages of Novo Nordisk's (NVO) Ozempic and Wegovy weight loss drugs.
Overlooked Stock: HIMS
Negative
The Motley Fool
18 hours ago
Why Hims & Hers Health Stock Is Plummeting Today
Shares of Hims & Hers Health (HIMS -24.30%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m.
Why Hims & Hers Health Stock Is Plummeting Today
Negative
Barrons
19 hours ago
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
Negative
CNBC
19 hours ago
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
The FDA announced on Friday that the shortage of semaglutide injection products like Novo Nordisk's Ozempic and Wegovy has been resolved. The FDA said Friday that it will start taking action against compounders for violations in the next 60 to 90 days.
Shares of Hims & Hers tumble 23% after FDA says semaglutide is no longer in shortage
Positive
24/7 Wall Street
20 hours ago
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?
Negative
Schaeffers Research
21 hours ago
Hims and Hers Stock Drops Weight as Earnings Loom
Hims & Hers Health Inc (NYSE:HIMS) stock has had a roller coaster week.
Hims and Hers Stock Drops Weight as Earnings Loom
Negative
Investors Business Daily
21 hours ago
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
HIMS stock fell after the FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. The post Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage appeared first on Investor's Business Daily.
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
Negative
Invezz
21 hours ago
HIMS stock crashes 25% on Friday after this key FDA update
Shares of Hims & Hers Health plunged a massive 25% on Friday to hit an intraday low of around $49.01. The massive crash came after the US Food and Drug Administration (FDA) announced the end of the shortage of Novo Nordisk's weight-loss drugs.
HIMS stock crashes 25% on Friday after this key FDA update
Neutral
Business Wire
23 hours ago
Hims & Hers Acquires US-based Peptide Facility
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the company's long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment.
Hims & Hers Acquires US-based Peptide Facility
Positive
Seeking Alpha
1 day ago
Hims & Hers Health: The Ultimate Pick For The Next Decade
Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. I provide multiple perspectives in this article, offering readers different viewpoints to draw their own conclusions. There are historical references, future valuations, and timeless investing lessons. There are five primary growth drivers that should continue to turbocharge HIMS' future revenue. I cover them all in detail.
Hims & Hers Health: The Ultimate Pick For The Next Decade
Charts implemented using Lightweight Charts™